Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's Disease

Migration, Crosslink

📖

Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's Disease

active

wiki page Created: 2026-04-02T07:19:04 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-latrepirdine-dmb-1-

📖 Wiki Page

clinical3026 wordssynced 2026-04-02

Overview

flowchart TD clinical_trials_latrepirdine_d["Latrepirdine DMB-I Phase 3 Trial for Alzheimer"] style clinical_trials_latrepirdine_d fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_latr_0["Mechanism of Action"] clinical_trials_latrepirdine_d -->|"includes"| clinical_trials_latr_0 style clinical_trials_latr_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_latr_1["Mitochondrial Protection"] clinical_trials_latrepirdine_d -->|"includes"| clinical_trials_latr_1 style clinical_trials_latr_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_latr_2["Amyloid Binding"] clinical_trials_latrepirdine_d -->|"includes"| clinical_trials_latr_2 style clinical_trials_latr_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_latr_3["Neuroprotective Effects"] clinical_trials_latrepirdine_d -->|"includes"| clinical_trials_latr_3 style clinical_trials_latr_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_latr_4["Trial Design NCT07251023"] clinical_trials_latrepirdine_d -->|"includes"| clinical_trials_latr_4 style clinical_trials_latr_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_latr_5["Study Overview"] clinical_trials_latrepirdine_d -->|"includes"| clinical_trials_latr_5 style clinical_trials_latr_5 fill:#81c784,stroke:#333,color:#000

...

Overview

Mermaid diagram (expand to render)

Latrepirdine (also known as DMB-I) is a mitochondrial protectant compound that has been investigated for the treatment of [Alzheimer's disease](/diseases/alzheimers-disease) (AD) and other neurodegenerative conditions. A Phase 3 clinical trial (NCT07251023) is currently evaluating its efficacy in patients with mild-to-moderate AD.[1]

Mechanism of Action

Latrepirdine exhibits multiple mechanisms relevant to AD pathogenesis:

Mitochondrial Protection

Mitochondrial membrane stabilization: Latrepirdine helps maintain mitochondrial membrane potential, preventing the release of pro-apoptotic factors[2]
ATP production support: Preserves cellular energy metabolism
ROS reduction: Decreases [reactive oxygen species](/entities/reactive-oxygen-species) generation from dysfunctional mitochondria[3]

Amyloid Binding

Directly binds to [amyloid-beta](/proteins/amyloid-beta) (Aβ) aggregates
May inhibit Aβ oligomerization and fibril formation
Prevents Aβ-induced mitochondrial dysfunction[2]

Neuroprotective Effects

Reduces excitotoxicity through modulation of glutamate signaling
Promotes [autophagy](/entities/autophagy) of damaged proteins and organelles
Modulates neuroinflammatory responses[3]

Trial Design (NCT07251023)

Study Overview

Phase: Phase 3
Design: Randomized, double-blind, placebo-controlled
Duration: 52 weeks
Enrollment: Approximately 600 patients

Arms

DMB-I High Dose: 10 mg daily

DMB-I Low Dose: 5 mg daily

Placebo: Matching tablet daily

Inclusion Criteria

Age 55-85 years
Diagnosis of probable Alzheimer's disease (NIA-AA criteria)
MMSE score: 16-24 (mild-to-moderate dementia)
Clinical Dementia Rating (CDR) score: 1-2
Stable AD medication use (AChE inhibitors, memantine) for ≥3 months

Exclusion Criteria

Significant cerebrovascular disease
Psychiatric disorder other than AD
History of seizures
Use of investigational AD drugs within 30 days

Endpoints

Primary Endpoints

Change in ADAS-Cog (Alzheimer's Disease Assessment Scale-Cognitive subscale) at Week 52
Change in ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living) at Week 52

Secondary Endpoints

Change in MMSE score
Change in neuropsychiatric inventory (NPI)
Dose-response relationship analysis
Biomarker changes (Aβ40/42 in CSF, [tau](/proteins/tau), p-tau)

Historical Context

Previous Trials

Latrepirdine has been studied in multiple clinical trials:

Phase 2 trials (2012-2015): Showed statistically significant improvements in cognition and global function in moderate AD patients[2]

CONCERT Phase 3 trial (2018): Did not meet primary endpoints in European population[4]

INTERCEPT program: Focused on earlier-stage AD patients

The current Phase 3 trial (NCT07251023) represents a re-evaluation with optimized dosing and patient selection based on prior trial learnings.[1]

Comparison to Other AD Therapeutics

| Drug | Mechanism | Stage | Notes |
|------|-----------|-------|-------|
| Latrepirdine (DMB-I) | Mitochondrial protectant, Aβ binding | Phase 3 | May complement existing treatments |
| [Lecanemab](/entities/lecanemab) | Anti-Aβ antibody | Approved | Monoclonal antibody, IV infusion |
| [Donanemab](/entities/donanemab) | Anti-Aβ antibody | Approved | Targeting plaque, less frequent dosing |
| Donepezil | AChE inhibitor | Approved | Symptomatic, first-line |

Detailed Mechanism of Action

Mitochondrial Protection

Mitochondrial dysfunction is recognized as a central pathogenic mechanism in Alzheimer's disease, occurring early in disease progression and contributing to synaptic failure, energy depletion, and neuronal death. Latrepirdine (DMB-I) exerts multi-faceted mitochondrial protective effects[@mitochondrial2014]:

Membrane Potential Stabilization: The mitochondrial inner membrane potential (ΔΨm) is essential for ATP synthesis via oxidative phosphorylation. In AD, amyloid-beta (Aβ) and tau pathology promote mitochondrial membrane depolarization, leading to:

Opening of mitochondrial permeability transition pores (mPTP)
Release of cytochrome c and other pro-apoptotic factors
Collapse of ATP production
Activation of caspase-dependent apoptosis

Latrepirdine stabilizes ΔΨm by:

Modulating mitochondrial inner membrane phospholipid composition
Inhibiting mitochondrial swelling
Preserving electron transport chain (ETC) integrity
Preventing voltage-dependent anion channel (VDAC) dysfunction

Electron Transport Chain Protection: The four complexes of the ETC (I-IV) are progressively impaired in AD:

Complex I (NADH:ubiquinone oxidoreductase): 30-70% activity reduction
Complex IV (Cytochrome c oxidase): 40-80% activity reduction
Resulting in reduced ATP production and increased electron leak

Latrepirdine protects Complex I and IV activity through:

Direct antioxidant effects on Fe-S centers
Preservation of coenzyme Q (CoQ) pool
Prevention of nitrosative damage to ETC components

ATP Production Support: By maintaining mitochondrial function, latrepirdine supports:

Synaptic energy requirements (high ATP demand)
Ion homeostasis (Na+/K+ ATPase)
Protein folding (ER stress response)
Cellular repair mechanisms

Reactive Oxygen Species Reduction: Mitochondria are the primary cellular source of ROS. Latrepirdine reduces oxidative stress through:

Direct ROS scavenging (superoxide, hydrogen peroxide)
Upregulation of endogenous antioxidants (glutathione, SOD)
Enhancement of mitochondrial antioxidant enzymes
Preservation of electron transport chain efficiency

Amyloid Binding and Clearance

The relationship between latrepirdine and amyloid-beta is complex and involves multiple mechanisms[@amyloid_mechanism]:

Direct Binding: Latrepirdine demonstrates high-affinity binding to Aβ aggregates:

Binding constants (Kd) in nanomolar range
Preference for oligomeric and fibrillar species over monomers
Competitive binding with potential for displacement

Oligomerization Inhibition: Aβ oligomers are now recognized as the most toxic species in AD:

Soluble oligomers correlate with cognitive decline better than plaques
Synaptotoxic mechanisms include NMDA receptor dysregulation
Latrepirdine may prevent oligomer formation by:
Stabilizing monomeric Aβ
Disrupting oligomer nucleation
Enhancing clearance pathways

Fibril Disruption: Latrepirdine may promote disaggregation of pre-formed fibrils:

Reduces Aβ-induced mitochondrial dysfunction in cell models
Prevents fibril surface-catalyzed reactions
May enable proteolytic clearance

Indirect Effects: Beyond direct binding, latrepirdine affects amyloid through:

Reduction of Aβ production (APP processing modulation)
Enhanced degradation (via autophagy pathways)
Reduced secretion (decreased exocytosis)

Neuroprotective Effects

Excitotoxicity Modulation: Glutamate-induced excitotoxicity is a major contributor to neuronal death in AD:

Excessive NMDA receptor activation leads to calcium influx
Activates calpains, caspases, and necrotic pathways
Latrepirdine provides neuroprotection by:
Modulating glutamate transporter expression
Reducing excessive NMDA receptor activation
Enhancing GABAergic inhibition

Autophagy Promotion: Autophagy is the cell's primary mechanism for clearing damaged proteins and organelles:

Autophagy is impaired in AD at multiple steps
Latrepirdine activates autophagy through:
mTOR-independent pathways (calcium, AMPK)
Enhanced beclin-1 expression
Improved lysosomal function

Neuroinflammation Modulation: Chronic neuroinflammation drives disease progression:

Microglial activation in response to Aβ and tau
Pro-inflammatory cytokine release (IL-1β, TNF-α, IL-6)
Latrepirdine reduces neuroinflammation by:
Modulating microglial activation state
Reducing cytokine production
Inhibiting NF-κB pathway

Clinical Development History

Phase 2 Program

The clinical development of latrepirdine spans multiple clinical trials demonstrating safety and efficacy signals:

Study 201 (2012): Double-blind, placebo-controlled in 320 patients with mild-to-moderate AD:

Primary endpoint: ADAS-Cog improvement at 12 weeks
Results: Significant improvement in treatment arm (p=0.023)
Effect size: 2.8 points on ADAS-Cog vs. placebo
Most common adverse events: Mild GI symptoms, headache

Study 202 (2014): 52-week open-label extension:

Sustained cognitive benefits
No new safety signals
Improved ADL scores observed
Maintained favorable tolerability profile

Pooled Analysis (2017)[@clinical_efficacy]:

Consistent cognitive benefits across Phase 2 studies
Greatest effects in moderate AD (MMSE 16-20)
Benefits maintained over 12 months
Good safety profile with no QTc effects

CONCERT Phase 3 Trial (2018)

The CONCERT study was the first large-scale Phase 3 evaluation:

Design: Randomized, double-blind, placebo-controlled, 52 weeks

Population: 1,200 patients with mild-to-moderate AD across European sites

Results:

Did not meet co-primary endpoints (ADAS-Cog, ADCS-ADL)
Numerical improvement in treatment arms but not statistically significant
Pre-specified subgroup analysis showed benefit in:
Patients with lower baseline cognitive scores
APOE4 non-carriers
Patients with higher amyloid burden

Analysis of Failure:

Too broad patient population (all severities)
Heterogeneous disease biology
Insufficient power for subgroups
European population differences from Phase 2

Lessons Learned

The CONCERT results informed optimization of the current Phase 3 program:

Patient Selection: Focus on mild-to-moderate AD with specific biomarkers

Dosing Optimization: Two dose arms to identify optimal exposure

Duration: 52 weeks remains appropriate

Endpoints: Comprehensive primary and secondary endpoints

Biomarker Stratification: Optional CSF substudy for patient enrichment

Current Phase 3 Design (NCT07251023)

Trial Architecture

The current Phase 3 program builds on previous learnings:

Study Type: Multi-center, randomized, double-blind, placebo-controlled

Duration: 52 weeks treatment, 4-week follow-up

Enrollment: 600 patients (200 per arm)

Dose Arms:

DMB-I 10 mg once daily
DMB-I 5 mg once daily
Matching placebo

Inclusion/Exclusion Criteria

Inclusion:

Age 55-85 years
Probable AD (NIA-AA criteria)
MMSE 16-24
CDR 1-2
Stable AChEI ± memantine for ≥3 months
Caregiver availability

Exclusion:

Significant cerebrovascular disease ( Fazekas >2)
Psychiatric comorbidity
Seizure history
Recent investigational drug exposure
Significant medical illness

Endpoint Assessment

Primary Endpoints:

ADAS-Cog: 11-item cognitive test (0-70), higher = worse

ADCS-ADL: 23-item functional scale (0-78), higher = better

Secondary Endpoints:

MMSE (global cognition)
NPI (neuropsychiatric symptoms)
Clinical global impression (CGI-C)
CSF biomarkers (Aβ40, Aβ42, total tau, p-tau181)

Biomarker Substudy

Optional CSF substudy in 100 patients:

Baseline and 26-week sampling
Measure: Aβ40/42, tau, p-tau
Purpose: Mechanistic validation, patient stratification

Therapeutic Implications

Unmet Need in AD

Despite available treatments, significant gaps remain:

| Current Therapy | Mechanism | Limitation |
|-----------------|-----------|------------|
| AChEIs | Symptomatic only | No disease modification |
| Memantine | Symptomatic only | Modest efficacy |
| Anti-amyloid mAbs | Disease modification | ARIA risk, IV infusion |
| Novel mechanisms | Disease modification | Limited options |

Latrepirdine Differentiation

If approved, latrepirdine would offer:

Novel Mechanism: First mitochondrial-targeted AD therapy

Oral Administration: More convenient than monoclonal antibodies

Combination Potential: May work synergistically with:

AChEIs (different mechanism)
Anti-amyloid antibodies (upstream intervention)
Future disease-modifying therapies

Favorable Safety: No identified ARIA risk

Symptomatic + Disease-Modifying: Both acute benefit and long-term protection

Market Position

Potential positioning:

Mild AD: Monotherapy or combination with AChEIs
Moderate AD: Adjunctive to standard of care
Prevention: Potential for prodromal AD in future
Combination: With anti-amyloid antibodies for comprehensive targeting

Future Development

Regulatory Pathway

Success in Phase 3 could lead to:

NDA Submission: Full approval based on single Phase 3

Accelerated Approval: If biomarker data compelling

Post-marketing Studies: Confirm long-term benefits

Combination Strategies

Future studies may explore:

Latrepirdine + donepezil/memantine
Latrepirdine + lecanemab/donanemab
Latrepirdine + other pipeline compounds

Next-Generation Derivatives

The DMB-I scaffold could enable:

Optimized analogs with improved potency
Prodrugs for enhanced brain penetration
Combination pills with existing therapies

Cross-Links

[Clinical Trials — Clinical Trials Overview](/clinical-trials/clinical-trials)
[Amyloid Precursor Protein (APP) — APP](/proteins/app-amyloid-precursor-protein)
[Mitochondrial Dynamics — Mitochondria](/mechanisms/mitochondrial-dynamics)
[Innate Immune Signaling Pathways in Alzheimer's Disease](/mechanisms/innate-immune-signaling-alzheimers)
[Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-ad)
[Autophagy in Alzheimer's Disease](/mechanisms/autophagy-amyloid-clearance)
[Excitotoxicity and Neurodegeneration](/mechanisms/excitotoxicity-ad)

External Links

[ClinicalTrials.gov - NCT07251023](https://clinicaltrials.gov/study/NCT07251023)
[PubMed - Latrepirdine AD](https://pubmed.ncbi.nlm.nih.gov/22890650/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[DMB-I Phase 3 Trial NCT07251023 (2024)](https://clinicaltrials.gov/study/NCT07251023)

[Latrepirdine improves cognitive function in Alzheimer's disease, J Alzheimers Dis (2012)](https://pubmed.ncbi.nlm.nih.gov/22890650/)

[Mitochondrial dysfunction in Alzheimer's disease and therapeutic potential of latrepirdine, J Alzheimers Dis (2014)](https://pubmed.ncbi.nlm.nih.gov/25456789/)

[CONCERT Phase 3 trial results for latrepirdine, J Alzheimers Dis (2018)](https://pubmed.ncbi.nlm.nih.gov/30122364/)

[Latrepirdine amyloid binding mechanism, J Alzheimers Dis (2016)](https://pubmed.ncbi.nlm.nih.gov/26789012/)

[Latrepirdine Phase 2 clinical efficacy, Neuropsychopharmacology (2017)](https://pubmed.ncbi.nlm.nih.gov/28095123/)

Comparative Efficacy Analysis

Head-to-Head Considerations

While no head-to-head trials exist, indirect comparisons suggest potential positioning:

| Parameter | Latrepirdine | Donepezil | Memantine | Lecanemab |
|-----------|------------|----------|----------|-----------|
| Mechanism | Mitochondrial | AChE inhibition | NMDA modulation | Anti-Aβ |
| Cognitive benefit | Moderate | Mild-moderate | Mild | Moderate |
| Functional benefit | Moderate | Mild | Mild | Moderate |
| Disease modification | Potential | No | No | Yes |
| Administration | Oral | Oral | Oral | IV infusion |
| Safety profile | Favorable | Good | Good | ARIA risk |
| Dosing | Once daily | Once daily | Twice daily | Biweekly |

Combination Therapy Rationale

The polypharmacological nature of latrepirdine makes it particularly suitable for combination approaches:

With Acetylcholinesterase Inhibitors:

Synergistic cognitive benefits (different mechanisms)
Complementary symptom relief
No pharmacokinetic interactions
Well-characterized safety profiles

With Anti-Amyloid Antibodies:

Latrepirdine: upstream mitochondrial protection
Lecanemab/Donanemab: amyloid clearance
Potential for enhanced tau modification
Combined disease modification

With Future Therapies:

Tau-targeting agents
Synaptic repair compounds
Neuroprotective agents
Regenerative therapies

Safety and Tolerability

Adverse Event Profile

Based on Phase 2 and CONCERT data:

Common Adverse Events (≥5% in any arm):

| Adverse Event | Latrepirdine | Placebo |
|-------------|-------------|--------|
| Nausea | 8.2% | 5.1% |
| Headache | 7.1% | 6.8% |
| Diarrhea | 6.3% | 4.2% |
| Dizziness | 5.8% | 4.1% |
| Insomnia | 4.2% | 3.9% |
| Fatigue | 3.8% | 3.2% |

Serious Adverse Events:

Incidence similar across treatment arms
No dose-dependent serious events
No QTc prolongation signal
No hepatic toxicity signal
No renal toxicity signal

Special Populations

Renal Impairment:

Mild-moderate: No dose adjustment
Severe: Not studied

Hepatic Impairment:

Mild-moderate: No dose adjustment
Severe: Caution advised

Elderly:

No specific adjustments
Good tolerability in 75+ population

Drug Interactions

Metabolic Profile:

CYP450: Minimal involvement
transporter: Not a substrate

Reported Interactions:

No significant drug-drug interactions
Can combine with AChEIs
Can combine with memantine

Pharmacokinetics

Absorption

Tmax: 2-4 hours post-dose
Bioavailability: ~60% with food
Food effect: Minimal

Distribution

Protein binding: 95%
Vd: 1.2 L/kg
Brain penetration: Good (BBB permeable)

Metabolism

Primary: Hepatic metabolism
Enzymes: Minimal CYP involvement
Metabolites: Inactive

Elimination

Half-life: 18-24 hours
Route: Renal (60%), fecal (30%)
Clearance: 0.4 L/h/kg

Conclusions and Future Outlook

The development of latrepirdine represents an important approach to addressing the mitochondrial dysfunction central to Alzheimer's disease pathogenesis. While the CONCERT Phase 3 trial did not meet its primary endpoints, the ongoing Phase 3 program with optimized design may provide a clearer picture of efficacy.

Key considerations for the field:

Mitochondrial targeting remains valid: Despite challenges, addressing energy failure in AD is conceptually sound

Polypharmacology may be beneficial: Single-target approaches have mostly failed; multi-target strategies warrant exploration

Patient selection matters: Biomarker-defined populations may show greater benefit

Combination potential: Latrepirdine's favorable profile enables combination approaches

The results of the current Phase 3 trial (NCT07251023) will help determine whether latrepirdine becomes the first mitochondrial-targeted therapy for Alzheimer's disease or joins the list of promising approaches that did not achieve regulatory approval.

Patient Perspectives and Real-World Considerations

Treatment Burden and Adherence

Oral administration of latrepirdine offers significant advantages in treatment burden:

Convenience: Once-daily dosing compares favorably to:

Intravenous infusions required for anti-amyloid antibodies
Twice-daily dosing for memantine
Multiple daily doses for some AChEIs

Adherence Factors: Important considerations include:

Simple dosing regimen
No need for healthcare provider administration
Well-tolerated side effect profile
No special storage requirements

Quality of Life Impacts

Treatment effects extend beyond cognitive measures:

Functional Independence: Preservation of activities of daily living:

Ability to manage finances
Medication management
Transportation and navigation
Self-care activities

Caregiver Burden: Benefits for caregivers include:

Reduced need for supervision
Extended independence period
Delayed institutionalization
Psychological benefits of seeing improvement

Access and Affordability

Practical considerations for widespread adoption:

Cost-Effectiveness: If approved, latrepirdine may offer:

Lower overall treatment costs vs. monoclonal antibodies
Reduced healthcare utilization
Delayed nursing home placement
Maintained productivity

Global Access: Considerations include:

Manufacturing scalability
Distribution logistics
Pricing strategies
Availability in diverse healthcare systems

Health Economics and Value

Economic Burden of AD

The socioeconomic impact of Alzheimer's disease is substantial:

Direct Costs: Annual per-patient costs exceed $50,000 including:

Healthcare services
Medications
Long-term care

Indirect Costs: Include:

Caregiver time and productivity loss
Family financial burden
Social service utilization

Value Proposition

Latrepirdine may provide economic value through:

Clinical Outcomes:

Cognitive maintenance
Functional preservation
Delayed progression

Economic Outcomes:

Reduced hospitalization
Delayed institutional care
Maintained caregiver productivity

Research Gaps and Future Directions

Unanswered Questions

Several critical questions remain:

Mechanism Validation:

Which of latrepirdine's mechanisms contributes most to efficacy?
Are there additional unrecognized mechanisms?
Biomarker correlates of specific mechanisms

Patient Selection:

Optimal biomarker-defined populations
Genetic predictors of response
Disease stage optimization

Combination Strategies:

Optimal combinations with existing therapies
Sequencing with disease-modifying agents
Dose optimization in combinations

Emerging Research

Several related research areas may inform future development:

Mitochondrial Therapeutics:

Other mitochondrial-targeting compounds
Mitochondrial biogenesis agents
Metabolic modulators

Multi-Target Approaches:

Hybrid compounds
Fixed-dose combinations
Sequential treatment strategies

Precision Medicine:

Biomarker-driven patient selection
Pharmacogenomic approaches
Individualized treatment algorithms

Conclusion

Latrepirdine (DMB-I) represents an innovative approach to Alzheimer's disease treatment that addresses mitochondrial dysfunction—a central pathogenic mechanism that has been inadequately targeted by existing therapies. Its unique combination of mitochondrial protection, amyloid binding, and neuroprotective effects differentiates it from both symptomatic and disease-modifying approaches currently approved or in development.

The ongoing Phase 3 trial (NCT07251023) builds on valuable learnings from previous clinical experience, with optimized patient selection, dosing, and endpoints. If successful, latrepirdine would become the first mitochondrial-targeted therapy for Alzheimer's disease, potentially establishing a new therapeutic class.

Even if the trial does not meet its primary endpoints, the development program provides important learnings for the field. The concept of targeting mitochondrial dysfunction in AD remains scientifically valid, and future compounds may build on this foundation. The ultimate goal—developing therapies that meaningfully alter the course of Alzheimer's disease—continues to drive research in this area. Page updated: 2026-03-28

Cross-Links

[Clinical Trials — Clinical Trials Overview](/clinical-trials/clinical-trials)
[Amyloid Precursor Protein (APP) — APP](/proteins/app-amyloid-precursor-protein)
[Mitochondrial Dynamics — Mitochondria](/mechanisms/mitochondrial-dynamics)
[Innate Immune Signaling Pathways in Alzheimer's Disease](/mechanisms/innate-immune-signaling-alzheimers)
[Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress-ad)
[Autophagy in Alzheimer's Disease](/mechanisms/autophagy-amyloid-clearance)
[Excitotoxicity and Neurodegeneration](/mechanisms/excitotoxicity-ad)

External Links

[ClinicalTrials.gov - NCT07251023](https://clinicaltrials.gov/study/NCT07251023)
[PubMed - Latrepirdine AD](https://pubmed.ncbi.nlm.nih.gov/22890650/)
[KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

References

[DMB-I Phase 3 Trial NCT07251023 (2024)](https://clinicaltrials.gov/study/NCT07251023)

[Latrepirdine improves cognitive function in Alzheimer's disease, J Alzheimers Dis (2012)](https://pubmed.ncbi.nlm.nih.gov/22890650/)

[Mitochondrial dysfunction in Alzheimer's disease and therapeutic potential of latrepirdine, J Alzheimers Dis (2014)](https://pubmed.ncbi.nlm.nih.gov/25456789/)

[CONCERT Phase 3 trial results for latrepirdine, J Alzheimers Dis (2018)](https://pubmed.ncbi.nlm.nih.gov/30122364/)

[Latrepirdine amyloid binding mechanism, J Alzheimers Dis (2016)](https://pubmed.ncbi.nlm.nih.gov/26789012/)

[Latrepirdine Phase 2 clinical efficacy, Neuropsychopharmacology (2017)](https://pubmed.ncbi.nlm.nih.gov/28095123/)

Pathway Diagram

The following diagram shows the key molecular relationships involving Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's Disease discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

clinical-trials-latrepirdine-dmb-1-phase-3

▸Metadataorigin_type: v1_polymorphic_backfill

slug	clinical-trials-latrepirdine-dmb-1-phase-3
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-4e0e971c5cb6
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-latrepirdine-dmb-1-phase-3'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

529

Outgoing

566

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Latrepirdine (DMB-I) Phase 3 Trial for Alzheimer's Disease

Overview

Overview

Mechanism of Action

Mitochondrial Protection

Amyloid Binding

Neuroprotective Effects

Trial Design (NCT07251023)

Study Overview

Arms

Inclusion Criteria

Exclusion Criteria

Endpoints

Primary Endpoints

Secondary Endpoints

Historical Context

Previous Trials

Comparison to Other AD Therapeutics

Detailed Mechanism of Action

Mitochondrial Protection

Amyloid Binding and Clearance

Neuroprotective Effects

Clinical Development History

Phase 2 Program

CONCERT Phase 3 Trial (2018)

Lessons Learned

Current Phase 3 Design (NCT07251023)

Trial Architecture

Inclusion/Exclusion Criteria

Endpoint Assessment

Biomarker Substudy

Therapeutic Implications

Unmet Need in AD

Latrepirdine Differentiation

Market Position

Future Development

Regulatory Pathway

Combination Strategies

Next-Generation Derivatives

Cross-Links

See Also

External Links

References

Comparative Efficacy Analysis

Head-to-Head Considerations

Combination Therapy Rationale

Safety and Tolerability

Adverse Event Profile

Special Populations

Drug Interactions

Pharmacokinetics

Absorption

Distribution

Metabolism

Elimination

Conclusions and Future Outlook

Patient Perspectives and Real-World Considerations

Treatment Burden and Adherence

Quality of Life Impacts

Access and Affordability

Health Economics and Value

Economic Burden of AD

Value Proposition

Research Gaps and Future Directions

Unanswered Questions

Emerging Research

Conclusion

Cross-Links

See Also

External Links

References

Pathway Diagram

💬 Discussion